Hypertrophic Scars and Keloids

  • A. Paul Kelly


The development of hypertrophic scars (HS) and keloids are two dreaded complications of cutaneous surgery. Keloids, though medically benign, are often psychologically and socially problematic. Hypertrophic scars are elevated, thickened, and are often red, pruritic, or painful. Hypertrophic scars usually stay within the confines of the precipitating trauma, while keloids invade surrounding clinically normal skin. Keloids may also be pruritic and painful. Hypertrophic scars usually develop rapidly after cutaneous trauma, whereas keloids develop slowly but continue to enlarge for months to years. In most instances, HS regress with therapy in contrast to keloids, which often recur during therapy or when therapy is discontinued. The differences and similarities of keloids and HS are listed in Table 8-1.
Table 8-1.

Keloids compared to hypertrophic scars.


Hypertrophic Scar Triamcinolone Acetonide Pressure Therapy Keloid Scar Intralesional Steroid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ketchum LD, Smith J, Robinson DW, Masters FW. The treatment of hypertrophic scar, keloid scar and scar contracture by triamcinolone acetonide. Plast Recostr Surg 1996;38:209–218.CrossRefGoogle Scholar
  2. 2.
    Kelly PA. Medical and surgical therapies for keloids. Dermatol Ther 2004;17:212–218.CrossRefPubMedGoogle Scholar
  3. 3.
    Berman B, Bieley HC. Adjunct therapies to surgical management of keloids. Dermatol Surg 1966;22:126–130.CrossRefGoogle Scholar
  4. 4.
    Giovannini UM. Treatment of scars by steroid injections. Wound Repair Regen 2002;17:212–218.Google Scholar
  5. 5.
    Kerckhove EV, Stappaerts K, Fieuws S, et al. The assessment of erythema and thickness on burn related scars during pressure garment therapy as a preventive measure for hypertrophic scarring. Burns 2005;6:Epub ahead of print.Google Scholar
  6. 6.
    Chang CH, Song JY, Park JH, Seo SW. The efficacy of magnetic disks for the treatment of earlobe hypertrophic scar. Ann Plast Surg 2005;54:566–569.CrossRefPubMedGoogle Scholar
  7. 7.
    Russell R, Horlock N, Gault D. Zimmer splintage: as simple effective treatment for keloids following ear piercing. Br J Plast Surg 2001;54:509–510.CrossRefPubMedGoogle Scholar
  8. 8.
    Kerckhove EV, Stappaerts K, Boeckx W, et al. Silicones in the rehabilitation of burns: a review and overview. Burns 2001;27:205–214.CrossRefPubMedGoogle Scholar
  9. 9.
    Hamanova H, Broz L. Topigel in the treatment of hypertrophic scars after burn injuries. Acta Chir Plast 2002;44:18–22.PubMedGoogle Scholar
  10. 10.
    Borgognoni L. Biological effects of silicone gel sheeting. Wound Repair Regen 2002;10:118–121.CrossRefPubMedGoogle Scholar
  11. 11.
    Gold MH. A controlled clinical trial of topical silicone gel sheeting in the treatment of hypertrophic scars and keloids. J Am Acad Dermatol 1994;30:506–507.CrossRefPubMedGoogle Scholar
  12. 12.
    Rusciani L, Rosse G, Bono R. Use of cryotherapy in the treatment of keloids. J Dermatol Surg Oncol 1993;19:529–534.PubMedGoogle Scholar
  13. 13.
    Ceilley RI, Barin RW. The combined use of cryosurgery and intralesional injections of suspension of fluorinated adrenocorticosteroids for reducing keloids and hypertrophic scars. J Dermatol Surg Oncol 1979;5;54.PubMedGoogle Scholar
  14. 14.
    Borok TL, Bray N, Sinclair I, et al. Role of ionizing irradiation for 343 keloids. Int J Radiat Oncol Biol Phys 1998;15:836–870.Google Scholar
  15. 15.
    Garg MK, Weiss P, Sharma AK, et al. Adjuvant high dose rate brachytherapy (Ir-192) in the management of keloids which have recurred after surgical excision and external beam radiation. Radiother Oncol 2004;73:233–236.CrossRefPubMedGoogle Scholar
  16. 16.
    Guix B, Henriquez I, Andres A, et al. Treatment of keloids by high-dose rate brachytherapy: a seven year study. Int J Radiat Oncol Biol Phys 2001;50:167–172.PubMedGoogle Scholar
  17. 17.
    Botwood N, Lewanski C, Lowdell C. The risks of treating keloids with radiotherapy. Br J Radiol 1999;72:1222–1224.PubMedGoogle Scholar
  18. 18.
    Bowes LE, Nouri K, Berman B, et al. Treatment of pigmented hypertrophic scars with the 585 nm pulsed dye laser and the 532 nm frequency-doubled Nd: YAG laser in the Q-switched and variable pulse modes: a comparative study. Dermatol Surg 2002;28:714–719.CrossRefPubMedGoogle Scholar
  19. 19.
    Clavere P, Bedane C, Bonnetblanc JM, Bonnafoux-Clavere A, Rousseau J. Postoperative interstitial radiotherapy of keloids by iridium 192: a retrospective study of 46 treated scars. Dermatology 1997;195:349–352.CrossRefPubMedGoogle Scholar
  20. 20.
    Alster TS, Williams CM. Treatment of keloid sternotomy scars with 5858 nm flashlamp-pumped pulsed-dye laser. Lancet 1995;345:1198–1200.CrossRefPubMedGoogle Scholar
  21. 21.
    Goldman MP, Fitzpatrick RE. Laser treatment of scars. Dermatol Surg 1995;21:685–687.PubMedGoogle Scholar
  22. 22.
    Connel PG, Harland CC. Treatment of keloid scars with pulsed dye laser and intralesional steroid. J Cutan Laser Ther 2000;2:147–150.Google Scholar
  23. 23.
    Berman B, Flores F. Recurrence rates of excised keloids treated with post operative triamcinolone acetonide injections or interferon alpha-2b injections. J Am Acad Dermatol 1997;37:755–757.CrossRefPubMedGoogle Scholar
  24. 24.
    Berman B, Duncan MR. Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J Am Acad Dermatol 1989;21:694–702.CrossRefPubMedGoogle Scholar
  25. 25.
    Conejo-Mir JS, Corbi R, Linares M. Carbon dioxide laser ablation associated with interferon alfa-2b injections reduces the recurrence of keloids. J Am Acad Dermatol 1998;39:1039.PubMedGoogle Scholar
  26. 26.
    Berman B, Kaufman J. Rolet study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002;47(Suppl):S209–S211.CrossRefPubMedGoogle Scholar
  27. 27.
    Berman B, Villa A. Imiquimod 5% cream for keloid management. Dermatol Surg 2003;29:1050–1051.CrossRefPubMedGoogle Scholar
  28. 28.
    Fitzpatrick RE. Treatment of inflamed hypertrophic scars using intralesional 5FU. Dermatol Surg 1999;25:224–232.CrossRefPubMedGoogle Scholar
  29. 29.
    Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585 nm flashlamp-pumped pulsed-eye laser treatments. Arch Dermatol 2002;138:1149–1155.CrossRefPubMedGoogle Scholar
  30. 30.
    Kontochristopoulos G, Stefanaki C, Panagiotopoulos A, et al. Intralesional 5-flurouracil in the treatment of keloids: an open clinical and histopathologic study. J Am Acad Dermatol 2005;52:474–479.CrossRefPubMedGoogle Scholar
  31. 31.
    Apikian M, Goodman G. Intralesional 5-fluorouracil in the treatment of keloid scars. Australas J Dermatol 2004;45:140–143.CrossRefPubMedGoogle Scholar
  32. 32.
    Nanda S, Reddy BSN. Intralesional 5-fluorouracil as a treatment modality for keloids. Dermatol Surg 2004;30:54–57.CrossRefPubMedGoogle Scholar
  33. 33.
    Espana A, Solano T, Quintanilla E. Bleomycin in the treatment of hypertrophic scars by multiple needle punctures. Dermatol Surg 2001;27:23–27.CrossRefPubMedGoogle Scholar
  34. 34.
    Lee RC, Doong H, Jellema AF. The response of burn scars to intralesional verapamil. Report of five cases. Arch Surg 1994;129:107–111.PubMedGoogle Scholar
  35. 35.
    Lawrence WT. Treatment of earlobe keloids with surgery plus adjuvant intralesional verapamil and pressure earrings. Ann Plast Surg 1996;37:167–169.CrossRefPubMedGoogle Scholar
  36. 36.
    D’Andrea F, Brongo S, Ferraro G, et al. Prevention and treatment of keloids with intralesional verapamil. Dermatology 2002;204:60–62.CrossRefPubMedGoogle Scholar
  37. 37.
    Kim A, DiCarlo J, Cohen C, et al. Are keloids really “gliloids”? High-level expression of gli-1 oncogene in keloids. J Am Acad Dermatol 2001;45:707–711.CrossRefPubMedGoogle Scholar
  38. 38.
    Ladin DA, Hou Z, Patel D, et al. p53 and apoptosis alterations in keloids and keloid fibroblasts. Wound Repair Regen 1998;6:28–37.CrossRefPubMedGoogle Scholar
  39. 39.
    Louro ID, McKie-Bell P, Gosnell H, et al. The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin. Cell Growth Differ 1999;10:503–516.PubMedGoogle Scholar
  40. 40.
    Soderberg T, Hallmans G, Bartholdson L. Treatment of keloids and hypertrophic scars with adhesive zinc tape. Scand J Plast Reconstr Surg 1982;16:261–266.CrossRefPubMedGoogle Scholar
  41. 41.
    Wong TW, Lee JY, Sheutt M, Chao SC. Relief of pain and itch associated with keloids on treatment with oxpentifylline. Br J Dermatol 1999;140;771–772.PubMedGoogle Scholar
  42. 42.
    Berman B, Duncan MR. Pentoxyfylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma, morphea skin and their production of collagen, glycosaminoglycans and fibronectin. Br J Dermatolol 1990;123:339–346.CrossRefGoogle Scholar
  43. 43.
    Lawrence WT. In search of the optimal treatment of keloids: report of a series and review of the literature. Ann Plast Surg 1991;27:164–178.CrossRefPubMedGoogle Scholar
  44. 44.
    Onwukwe MF. Treating keloids by surgery and methotrexate. Arch Dermatol 1980;116:158.CrossRefPubMedGoogle Scholar
  45. 45.
    Mayou BJ. D-penicillamine in the treatment of keloids. Br J Dermatol 1981;105:87–89.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • A. Paul Kelly
    • 1
  1. 1.Department of Internal Medicine, King/Drew Medical CenterDivision of Dermatology, Charles R. Drew University of Medicine and ScienceLos AngelesUSA

Personalised recommendations